|Reactivity||Human, Mouse, Rat, Horse, Dog|
|Calculated MW||36568 Da|
|Application & Usage||Western blotting (0.5-4 µg/ml). However, the optimal conditions should be determined individually. The antibody recognizes PAR4 in samples from of human, mouse, and rat origins. Reactivity to other species has not been tested.|
|Other Names||Par4, PAR -4 induced by effectors of apoptosis , PAWR , PRKC Apoptosis WT1 Regulator Prostate Apoptosis Response Protein 4 TRANSCRIPTIONAL R|
|Formulation||100 µg (0.5 mg/ml) purified rabbit polyclonal antibody in phosphate-buffered saline (PBS) containing 30% glycerol, 0.5% BSA and 0.01% thimerosal.|
|Handling||The antibody solution should be gently mixed before use.|
|Reconstitution & Storage||-20 °C|
|Precautions||PAR4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Pro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down- regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1.|
|Cellular Location||Cytoplasm. Nucleus. Note=Mainly cytoplasmic in absence of apoptosis signal and in normal cells. Nuclear in most cancer cell lines. Nuclear entry seems to be essential but not sufficient for apoptosis (By similarity). Nuclear localization includes nucleoplasm and PML nuclear bodies.|
|Tissue Location||Widely expressed. Expression is elevated in various neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer, Parkinson and Huntington diseases and stroke. Down-regulated in several cancers|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Five ionomycin-inducible complementary cDNAs, designated PAR1, 2, 3, 4 and 5, have been isolated from the prostate cancer cell line AT-3. Nucleotide sequencing identified PAR1 as the rat homolog of monkeyP-1, PAR2 as the injury-inducible gene HB-EGF, and PAR3 as the serum-induced gene cyr-61. PAR4 and PAR5 sequences were not found to correspond to any previously described proteins. PAR4 (prostate apoptosis response-4) is specifically expressed by cells entering apoptosis and is not inducible by growth factor stimulation, oxidative stress and necrosis, or growth arrest. The PAR4 gene encodes a 38 kDa protein with a putative nuclear localization signal and carboxy terminal leucine zipper.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.